Optiscan Imaging Limited Share Price

Equities

OIL

AU000000OIL4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 07:10:05 29/04/2024 BST 5-day change 1st Jan Change
0.085 AUD 0.00% Intraday chart for Optiscan Imaging Limited -4.49% +1.19%

Financials

Sales 2022 2.25M 1.48M 118M Sales 2023 2.62M 1.72M 137M Capitalization 50.1M 32.87M 2.62B
Net income 2022 -4M -2.62M -209M Net income 2023 -4M -2.62M -209M EV / Sales 2022 28.5 x
Net cash position 2022 3.98M 2.61M 208M Net cash position 2023 463K 304K 24.21M EV / Sales 2023 19 x
P/E ratio 2022
-16.1 x
P/E ratio 2023
-11.4 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 38.52%
More Fundamentals * Assessed data
Dynamic Chart
1 week-4.49%
Current month+11.84%
1 month+11.84%
3 months+6.25%
Current year+1.19%
More quotes
1 week
0.08
Extreme 0.081
0.09
1 month
0.08
Extreme 0.076
0.11
Current year
0.07
Extreme 0.071
0.11
1 year
0.07
Extreme 0.071
0.13
3 years
0.07
Extreme 0.071
0.46
5 years
0.01
Extreme 0.013
0.47
10 years
0.01
Extreme 0.013
0.47
More quotes
Managers TitleAgeSince
Chief Executive Officer - 05/05/21
Director of Finance/CFO - 25/04/22
Chief Operating Officer - 11-05
Members of the board TitleAgeSince
Chairman - 18/04/21
Director/Board Member - 13/06/22
Director/Board Member - 28/07/21
More insiders
Date Price Change Volume
29/04/24 0.085 0.00% 156 348
26/04/24 0.085 -1.16% 18,535
24/04/24 0.086 +4.88% 81,152
23/04/24 0.082 0.00% 67,000
22/04/24 0.082 -7.87% 121,684

Delayed Quote Australian S.E., April 29, 2024 at 07:10 am

More quotes
Optiscan Imaging Limited is an Australia-based company, which is engaged in the development, manufacturing and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The Company’s technology enables real-time, non-destructive, three-dimensional (3D), in-vivo imaging at the single-cell level. It provides real-time microscopic imaging tools to healthcare providers and researchers to enable the early detection and management of disease. Its InVivage device is developed for clinical use in oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a hand-held, confocal microscope designed for pre-clinical use. This device is targeted for use by universities and medical research institutions to explore potential applications of the technology through laboratory testing of tissue samples.
More about the company